Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 2386 | 1.2 |
09:38 ET | 700 | 1.22 |
09:39 ET | 500 | 1.2175 |
09:41 ET | 200 | 1.22 |
09:43 ET | 1631 | 1.2255 |
09:48 ET | 500 | 1.23 |
09:50 ET | 200 | 1.23 |
09:52 ET | 200 | 1.23 |
09:54 ET | 400 | 1.23 |
09:56 ET | 200 | 1.23 |
09:57 ET | 505 | 1.23 |
09:59 ET | 3305 | 1.2298 |
10:01 ET | 5514 | 1.2272 |
10:03 ET | 400 | 1.23 |
10:06 ET | 750 | 1.23 |
10:08 ET | 450 | 1.2225 |
10:10 ET | 200 | 1.23 |
10:12 ET | 200 | 1.23 |
10:14 ET | 500 | 1.23 |
10:17 ET | 200 | 1.23 |
10:19 ET | 390 | 1.23 |
10:21 ET | 3304 | 1.225 |
10:24 ET | 100 | 1.225 |
10:26 ET | 400 | 1.23 |
10:30 ET | 300 | 1.23 |
10:32 ET | 225 | 1.23 |
10:33 ET | 7583 | 1.22 |
10:35 ET | 20000 | 1.2199 |
10:42 ET | 300 | 1.22 |
10:46 ET | 300 | 1.22 |
10:48 ET | 300 | 1.22 |
10:51 ET | 300 | 1.22 |
10:53 ET | 300 | 1.22 |
10:57 ET | 1995 | 1.21 |
11:00 ET | 2684 | 1.22 |
11:02 ET | 400 | 1.22 |
11:04 ET | 400 | 1.22 |
11:06 ET | 11046 | 1.22 |
11:09 ET | 300 | 1.22 |
11:13 ET | 4115 | 1.21 |
11:15 ET | 200 | 1.22 |
11:20 ET | 200 | 1.22 |
11:24 ET | 400 | 1.219 |
11:26 ET | 300 | 1.22 |
11:27 ET | 1320 | 1.215 |
11:29 ET | 373 | 1.22 |
11:33 ET | 227 | 1.22 |
11:36 ET | 268 | 1.22 |
11:38 ET | 300 | 1.22 |
11:42 ET | 2200 | 1.22 |
11:45 ET | 200 | 1.22 |
11:49 ET | 218 | 1.22 |
11:54 ET | 4399 | 1.22 |
11:58 ET | 461 | 1.22 |
12:00 ET | 200 | 1.22 |
12:07 ET | 400 | 1.21 |
12:12 ET | 14412 | 1.21 |
12:14 ET | 6000 | 1.21 |
12:20 ET | 2200 | 1.21 |
12:21 ET | 338 | 1.22 |
12:32 ET | 230 | 1.211 |
12:34 ET | 1199 | 1.21 |
12:36 ET | 2000 | 1.2103 |
01:03 ET | 2093 | 1.21 |
01:06 ET | 1929 | 1.21 |
01:10 ET | 300 | 1.215 |
01:21 ET | 100 | 1.215 |
01:32 ET | 800 | 1.21 |
01:33 ET | 11795 | 1.21 |
01:35 ET | 668 | 1.22 |
01:50 ET | 4050 | 1.21 |
01:51 ET | 200 | 1.21 |
01:53 ET | 249 | 1.215 |
02:06 ET | 300 | 1.21 |
02:09 ET | 1502 | 1.21 |
02:13 ET | 9104 | 1.2008 |
02:15 ET | 200 | 1.2 |
02:24 ET | 200 | 1.19 |
02:29 ET | 11748 | 1.18 |
02:31 ET | 100 | 1.18 |
02:33 ET | 200 | 1.1876 |
02:36 ET | 100 | 1.1874 |
02:38 ET | 5514 | 1.185 |
02:44 ET | 224 | 1.183 |
02:47 ET | 206 | 1.185 |
02:58 ET | 200 | 1.185 |
03:05 ET | 987 | 1.185 |
03:07 ET | 200 | 1.185 |
03:16 ET | 1800 | 1.185 |
03:20 ET | 200 | 1.185 |
03:23 ET | 700 | 1.19 |
03:25 ET | 647 | 1.19 |
03:32 ET | 300 | 1.19 |
03:36 ET | 5100 | 1.185 |
03:38 ET | 500 | 1.187 |
03:39 ET | 700 | 1.19 |
03:43 ET | 760 | 1.18 |
03:45 ET | 100 | 1.19 |
03:48 ET | 1300 | 1.19 |
03:50 ET | 100 | 1.19 |
03:54 ET | 3910 | 1.19 |
03:56 ET | 1147 | 1.19 |
03:57 ET | 1592 | 1.185 |
03:59 ET | 11268 | 1.18 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 92.2M | 8.6x | --- |
Spero Therapeutics Inc | 72.4M | 4.2x | --- |
2Seventy Bio Inc | 243.1M | -1.5x | --- |
Fortress Biotech Inc | 38.7M | -0.4x | --- |
Cannabis Bioscience International Holdings Inc | 7.3M | 0.0x | --- |
MDxHealth SA | 98.4M | -1.4x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $92.2M |
---|---|
Revenue (TTM) | $119.6M |
Shares Outstanding | 78.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $0.14 |
Book Value | $-0.70 |
P/E Ratio | 8.6x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 7.1x |
Operating Margin | 4.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.